Gastroenterology Laboratory, Department of Biomedical Sciences, College of Veterinary Medicine, Tuskegee University, Tuskegee, AL 36088, United States.
Physiol Behav. 2010 Dec 2;101(5):649-52. doi: 10.1016/j.physbeh.2010.09.012. Epub 2010 Sep 24.
Cholecystokinin (CCK) is a satiety peptide and a potential anti-diabetic agent, which exists in different forms (e.g. CCK-8 and CCK-33). In normal rats, CCK-8 and 33 stimulate insulin secretion similarly but their satiety effects vary. In diabetic rats, those effects require testing. Here, we compared size of the first meal (10% sucrose test diet), intermeal interval (IMI, time between first and second meal) and satiety ratio (SR, amount of satiation produced by every unit of food consumed in the first meal) by CCK-8 or 33 (0, 1, 3, 5nmol/kg) intraperitoneally in streptozotocin-injected (diabetic) and citrate buffer-injected (control) rats. We found that both peptides reduce meal size in diabetic and control rats with no difference between groups, CCK-33 (5nmol) prolonged IMI in diabetic rats and CCK-8 and CCK-33 increased satiety ratio in control rats, but only CCK-8 increased it in the diabetic group. Therefore, CCK-8 increases the satiety ratio in diabetic rats more than CCK-33.
胆囊收缩素（CCK）是一种饱腹感肽，也是一种潜在的抗糖尿病药物，它以不同的形式存在（如 CCK-8 和 CCK-33）。在正常大鼠中，CCK-8 和 33 同样刺激胰岛素分泌，但它们的饱腹感效果不同。在糖尿病大鼠中，需要对这些效果进行测试。在这里，我们比较了 CCK-8 或 33（0、1、3、5nmol/kg）腹腔注射（糖尿病）和柠檬酸缓冲液注射（对照）大鼠中 CCK-8 或 33（0、1、3、5nmol/kg）对第一餐（10%蔗糖测试饮食）大小、餐间间隔（IMI，第一餐和第二餐之间的时间）和饱食率（SR，第一餐消耗的每单位食物产生的饱腹感）的影响。我们发现，两种肽类都能减少糖尿病和对照组大鼠的进食量，且组间无差异，CCK-33（5nmol）延长了糖尿病大鼠的 IMI，CCK-8 和 CCK-33 增加了对照组大鼠的饱食率，但只有 CCK-8 增加了糖尿病组的饱食率。因此，CCK-8 比 CCK-33 更能增加糖尿病大鼠的饱食率。
